PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and Cost-Effectively

Article

Pharmaceutical Executive

PAREXEL, an innovator of global biopharmaceutical services, introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.

PAREXEL Biotech combines the company’s expertise and global infrastructure with a model that is aligned to this specific segment, providing enhanced consulting and development capabilities through a new biotech-focused team and organizational structure. This team led by James Anthony and Graciela Racaro, will help emerging companies minimize complexity, reduce costs, and accelerate timelines through the use of many different strategies and services. Those services and strategies include global regulatory consulting, patient recruitment services, trial execution services, Real World Evidence programs, and much more.

Recent Videos
Most Effective Strategies to Close the Innovation Gap in Women’s Health
Root Causes of Innovation Gap in Women’s Health
Fred Aslan
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Fred Aslan
Dr. Dina Radenkovic, CEO, Gameto
Recent Regulatory Impacts on the Pain-Management Space
Fred Aslan
Related Content